Home/Indications/Oncology/Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Oncology 28 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Oncology indication. Non-Small Cell Lung Cancer has 28 FDA-approved novel treatments, led by Bristol-Myers Squibb across 59 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Non-Small Cell Lung Cancer Market Leaders

Companies with the most FDA-approved novel Non-Small Cell Lung Cancer drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

ALECENSA - alectinib hydrochloride capsule

Medicine Invention Design, Inc

Estimated · aging NCT05987956

Q4 2026

SKB264

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Estimated · aging NCT06448312

Q4 2026

SYS6010

CSPC Megalith Biopharmaceutical Co.,Ltd.

Estimated · aging NCT07376382

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Non-Small Cell Lung Cancer Treatments by Mechanism

Top 12 mechanisms across 201 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

40 trials 14 active 17 sponsors

Programmed Death Ligand-1 Blocker

27 trials 13 active 8 sponsors

Programmed Death Receptor-1 Blocking Antibody

56 trials 11 active 10 sponsors

Endoglycosidase

25 trials 3 active 2 sponsors

KRAS G12C

5 trials 3 active 2 sponsors

Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase

23 trials 2 active 6 sponsors

Vascular Endothelial Growth Factor Inhibitor

9 trials 2 active 7 sponsors

DNA

3 trials 2 active 3 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

2 trials 2 active 1 sponsor

Vascular Endothelial Growth Factor Receptor 2 Antagonist

8 trials 1 active 1 sponsor

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

2 trials 1 active 2 sponsors

EGFR/ERBB2

1 trials 1 active 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Non-Small Cell Lung Cancer Clinical Pipeline by Phase

1869 industry-sponsored trials across 583 sponsors

Showing 32 of 32 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Rigel Pharmaceuticals	Pralsetinib	Kinase Inhibitor [EPC]	RECRUITING	2027-07-30	NCT07704658
AstraZeneca	Osimertinib+cisplatin or carboplatin + pemetrexed Edit	—	RECRUITING	2030-05-18	NCT07279935
Novartis	dabrafenib	—	RECRUITING	2032-12-28	NCT03340506
Pfizer	crizotinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-03-21	NCT05160922
Pfizer	Lorlatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2029-10-25	NCT05144997
Eli Lilly	Selpercatinib	Kinase Inhibitor [EPC]	NOT YET RECRUITING	2029-10	NCT07822880
Pfizer	tucatinib	Kinase Inhibitor [EPC]	NOT YET RECRUITING	2032-03-13	NCT07768358
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-08-21	NCT03715205
Roche	—	—	COMPLETED	2023-11-30	NCT04180176
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	COMPLETED	2023-10-27	NCT04416633
Pfizer	Dacomitinib	DDR1/DDR2/EGFR/EPHA6/HER1/ERBB2/HER4/LCK/MNK1	COMPLETED	2022-10-15	NCT04511533
Pfizer	Lorlatinib	Kinase Inhibitor [EPC]	COMPLETED	2022-07-20	NCT04541706
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-04-07	NCT03285763
AstraZeneca	Osimertinib	—	COMPLETED	2020-04-15	NCT03853551
Bristol-Myers Squibb	Nivolumab	Endoglycosidase [EPC]	COMPLETED	2019-07-17	NCT03444766
Boehringer Ingelheim	Afatinib	—	COMPLETED	2019-03-28	NCT02514174
Catalysis SL	—	—	COMPLETED	2019-03-15	NCT03550482
Bristol-Myers Squibb	nab-paclitaxel	—	COMPLETED	2017-07-14	NCT02151149
Boehringer Ingelheim	Afatinib	—	COMPLETED	2017-05-17	NCT02208843
Roche	erlotinib [Tarceva]	—	COMPLETED	2015-01	NCT01609543
Roche	Erlotinib	—	COMPLETED	2014-12	NCT02000531
Roche	erlotinib [Tarceva]	—	COMPLETED	2013-11	NCT01287754
Betta Pharmaceuticals Co., Ltd.	Icotinib	—	COMPLETED	2013-10	NCT01465243
Roche	Erlotinib	—	COMPLETED	2013-09	NCT01230710
Eli Lilly	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	COMPLETED	2011-03	NCT01020786
AstraZeneca	Gefitinib	Kinase Inhibitor [EPC]	COMPLETED	2011-01	NCT00770588
AstraZeneca	—	—	COMPLETED	2010-04	NCT01000740
Roche	erlotinib [Tarceva]	—	COMPLETED	2009-11	NCT01066884
Galvanize Therapeutics, Inc.	Nivolumab plus Platinum Doublet Chemotherapy	—	TERMINATED	2024-02-08	NCT05583188
Hikma Pharmaceuticals LLC	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	TERMINATED	2018-11-14	NCT03460678
Boehringer Ingelheim	Afatinib	—	TERMINATED	2016-08-26	NCT02695290
Betta Pharmaceuticals Co., Ltd.	Icotinib	—	SUSPENDED	2015-12	NCT01720901

Showing 100 of 410 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	QL2107	—	RECRUITING	2026-12	NCT06754644
Mabscale, LLC	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2026-12	NCT05654454
Akeso	Ivonescimab, docetaxel	—	RECRUITING	2027-05	NCT06928389
Amgen	Sotorasib	KRAS G12C	RECRUITING	2027-06-30	NCT05920356
Changchun GeneScience Pharmaceutical Co., Ltd.	Nano-crystalline Megestrol Acetate Oral Suspension	—	RECRUITING	2027-06-30	NCT07150663
Qilu Pharmaceutical Co., Ltd.	QL1706 injection	—	RECRUITING	2027-08-31	NCT05487391
Bayer	Sevabertinib	EGFR/ERBB2	RECRUITING	2027-10-28	NCT06452277
Eli Lilly	LY3537982	—	RECRUITING	2027-11	NCT06119581
Allist Pharmaceuticals, Inc.	Firmonertinib Mesilate Tablets	—	RECRUITING	2027-12	NCT06956001
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-12	NCT07178795
Revolution Medicines, Inc.	daraxonrasib	—	RECRUITING	2027-12-01	NCT06881784
OSE Immunotherapeutics	OSE2101	—	RECRUITING	2027-12-15	NCT06472245
3D Medicines (Sichuan) Co., Ltd.	Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection	—	RECRUITING	2027-12-30	NCT06123754
RemeGen Co., Ltd.	RC148 plus Carboplatin and Paclitaxel	—	RECRUITING	2027-12-31	NCT07416474
Merck	Calderasib	—	RECRUITING	2028-01-24	NCT06345729
Merck	Sacituzumab tirumotecan	—	RECRUITING	2028-01-25	NCT06170788
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH-1028 tablets	—	RECRUITING	2028-02-01	NCT06080776
Shanghai JMT-Bio Inc.	Glumetinib	—	RECRUITING	2028-02-15	NCT06829459
Pfizer	PF-08046054	—	RECRUITING	2028-03-10	NCT07144280
AstraZeneca	Osimertinib	—	RECRUITING	2028-03-21	NCT06350097
Multitude Therapeutics Inc.	AMT-116	—	RECRUITING	2028-03-30	NCT07718737
Summit Therapeutics	Ivonescimab Injection	—	RECRUITING	2028-04	NCT06767514
Betta Pharmaceuticals Co., Ltd.	Befotertinib + Icotinib placebo	—	RECRUITING	2028-04-30	NCT06041776
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2028-08-31	NCT07416994
InxMed (Shanghai) Co., Ltd.	IN10018 in combination with D-1553	—	RECRUITING	2028-09	NCT07174908
Pfizer	Sigvotatug Vedotin	—	RECRUITING	2028-09-05	NCT06758401
NovoCure GmbH	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2028-10	NCT06216301
Mirati Therapeutics Inc.	Adagrasib	KRAS G12C	RECRUITING	2028-10-31	NCT04613596
Allist Pharmaceuticals, Inc.	Firmonertinib	—	RECRUITING	2028-10-31	NCT07010419
Roche	Divarasib	—	RECRUITING	2028-11-30	NCT06793215
AbbVie	Telisotuzumab Vedotin	—	RECRUITING	2028-12	NCT04928846
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2028-12	NCT06838273
Bristol-Myers Squibb	Iza-bren	—	RECRUITING	2028-12-15	NCT07100080
BioNTech SE	Pumitamig	—	RECRUITING	2029-01	NCT06712316
Nuvation Bio Inc.	Taletrectinib	—	RECRUITING	2029-01	NCT06564324
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2029-01-12	NCT06422143
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2029-01-29	NCT07291037
Beijing Pearl Biotechnology Limited Liability Company	Vebreltinib combined with platinum-based doublet chemotherapy.	—	RECRUITING	2029-02	NCT06930794
Pfizer	PF-08634404	—	RECRUITING	2029-02-27	NCT07222566
Eli Lilly	Olomorasib	—	RECRUITING	2029-05	NCT06890598
Dizal (Jiangsu) Pharmaceutical Co., Ltd.	sunvozertinib	—	RECRUITING	2029-09	NCT07182682
Mirati Therapeutics Inc.	Adagrasib	KRAS G12C	RECRUITING	2029-09-07	NCT06875310
Allist Pharmaceuticals, Inc.	JAB-21822	—	RECRUITING	2029-09-30	NCT06416410
Revolution Medicines, Inc.	zoldonrasib	—	RECRUITING	2029-10	NCT07777822
Nuvalent Inc.	Neladalkib (NVL-655)	—	RECRUITING	2029-12	NCT06765109
AbbVie	ABBV-1480	—	RECRUITING	2029-12	NCT07756645
Merck	Calderasib	—	RECRUITING	2029-12-07	NCT07190248
AstraZeneca	Datopotamab Deruxtecan	—	RECRUITING	2029-12-28	NCT06357533
Shanghai Henlius Biotech	HLX43	—	RECRUITING	2030-01-15	NCT07459751
Daiichi Sankyo	Trastuzumab Deruxtecan	—	RECRUITING	2030-04-24	NCT06899126
Astellas	Setidegrasib	—	RECRUITING	2030-06-30	NCT07566052
Genfleet Therapeutics (Shanghai) Inc.	GFH375	—	RECRUITING	2030-06-30	NCT07668752
AstraZeneca	Rilvegostomig	—	RECRUITING	2030-07-01	NCT06692738
Bristol-Myers Squibb	Nivolumab	Endoglycosidase [EPC]	RECRUITING	2030-07-30	NCT06561386
Nuvation Bio Inc.	Taletrectinib	—	RECRUITING	2030-08-30	NCT07154706
AbbVie	Telisotuzumab Adizutecan	—	RECRUITING	2030-09	NCT07155187
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2030-09-18	NCT07361497
AstraZeneca	Rilvegostomig	—	RECRUITING	2030-11-18	NCT06627647
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068，adebelizumab and platinum-based chemotherapy	—	RECRUITING	2030-12	NCT07170995
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2030-12	NCT07640789
InSightec	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2031-06-01	NCT05317858
Bristol-Myers Squibb	BMS-986504	—	RECRUITING	2031-08-12	NCT07063745
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2031-10-14	NCT07361510
Candel Therapeutics, Inc.	Aglatimagene Besadenovec	—	RECRUITING	2031-10-22	NCT07660094
Bristol-Myers Squibb	Iza-bren	—	RECRUITING	2031-12-30	NCT07680790
Roche	Divarasib	—	RECRUITING	2032-01-31	NCT07541170
Boehringer Ingelheim	Zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2032-02-26	NCT07195695
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2032-12	NCT07642024
Merck	Calderasib	—	RECRUITING	2032-12-15	NCT07554339
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2033-05-16	NCT06623422
Merck	Sacituzumab tirumotecan	—	RECRUITING	2034-02-21	NCT06312137
Merck	Intismeran	—	RECRUITING	2034-08-22	NCT07513376
Eikon Therapeutics	EIK1001	—	RECRUITING	2035-12-31	NCT07365319
AbbVie	Standard of Care	—	RECRUITING	2036-11	NCT07005102
Merck	Calderasib	—	RECRUITING	2039-10-26	NCT07431827
Akeso	Cadonilimab (AK104)	—	RECRUITING	2026-10-28	NCT06617416
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	D-1553 Tablet	—	RECRUITING	2026-10	NCT06300177
Beijing Pearl Biotechnology Limited Liability Company	PLB1001	—	RECRUITING	2026-09-30	NCT05989542
Shenyang Sunshine Pharmaceutical Co., LTD.	SSGJ-707	—	RECRUITING	2026-07-30	NCT06980272
Hansoh BioMedical R&D Company	HS-20117	—	RECRUITING	2026-06-01	NCT06417008
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2026-02	NCT06430437
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules	—	RECRUITING	2025-08	NCT05922345
Betta Pharmaceuticals Co., Ltd.	Ensartinib	—	RECRUITING	2025-06-01	NCT05341583
TYK Medicines, Inc	TY-9591	—	RECRUITING	2025-05	NCT05382728
Laboratorio Elea Phoenix S.A.	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2024-08	NCT05668650
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Almonertinib	—	RECRUITING	2024-07-15	NCT04951635
Medicine Invention Design, Inc	ALECENSA - alectinib hydrochloride capsule	—	ACTIVE NOT RECRUITING	2026-11-18	NCT05987956
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	ACTIVE NOT RECRUITING	2026-12	NCT06382129
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A2009 monotherapy	—	ACTIVE NOT RECRUITING	2026-12	NCT06671379
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	ACTIVE NOT RECRUITING	2026-12	NCT06711900
Amgen	ABP 234	—	ACTIVE NOT RECRUITING	2026-12-14	NCT06430866
Pfizer	Avelumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-12-31	NCT05059522
Qilu Pharmaceutical Co., Ltd.	QL2107	—	ACTIVE NOT RECRUITING	2026-12-31	NCT07162883
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2027-01-08	NCT05221840
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2027-01-11	NCT06417814
Merck	Sacituzumab Govitecan	—	ACTIVE NOT RECRUITING	2027-01-12	NCT05609968
Roche	Alectinib	—	ACTIVE NOT RECRUITING	2027-01-19	NCT05170204
Celltrion	CT-P51	—	ACTIVE NOT RECRUITING	2027-02	NCT06939595
Bristol-Myers Squibb	Repotrectinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-02-16	NCT06140836
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	ACTIVE NOT RECRUITING	2027-05	NCT06670196

Showing 100 of 842 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
ToLymph Inc.	SMS001	—	RECRUITING	2026-11-18	NCT06693336
Roche	Alectinib	—	RECRUITING	2026-11-30	NCT04302025
Innovent Biologics (Suzhou) Co. Ltd.	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	RECRUITING	2026-11-30	NCT07122687
Lantern Pharma Inc.	LP-300	—	RECRUITING	2026-12	NCT05456256
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316	—	RECRUITING	2026-12	NCT05482568
3D Medicines (Sichuan) Co., Ltd.	Lenvatinib + Envafolimab	—	RECRUITING	2026-12	NCT05024214
One-carbon Therapeutics AB	TH9619	—	RECRUITING	2026-12	NCT07151040
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT05956587
Akeso	AK129(dose 1)	—	RECRUITING	2026-12	NCT06943820
AP Biosciences Inc.	AP203	—	RECRUITING	2026-12	NCT05473156
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1826；Adebrelimab；SHR-8068；Bevacizumab	—	RECRUITING	2026-12	NCT06844474
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-12-15	NCT04585750
GV20 Therapeutics	GV20-0251	—	RECRUITING	2026-12-15	NCT05669430
HC Biopharma Inc.	HC010	—	RECRUITING	2026-12-30	NCT07169552
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
MediLink Therapeutics (Suzhou) Co., Ltd.	YL201	—	RECRUITING	2027-01	NCT07208773
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2027-01-31	NCT07202364
Genelux Corporation	Olvimulogene nanivacirepvec	—	RECRUITING	2027-02	NCT06463665
GI Innovation, Inc.	GI-108	—	RECRUITING	2027-02	NCT07172802
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-02-14	NCT07467863
Aulos Bioscience, Inc.	AU-007	—	RECRUITING	2027-02-28	NCT05267626
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Ellipses Pharma	EP0031	—	RECRUITING	2027-03	NCT05443126
Doma Biopharmaceutical（Suzhou）Co., Ltd.	DM005	—	RECRUITING	2027-03	NCT06515990
Allist Pharmaceuticals, Inc.	JAB-21822	—	RECRUITING	2027-03	NCT05288205
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-03-14	NCT07641023
BeOne Medicines	BGB-B2033	—	RECRUITING	2027-03-31	NCT06427941
Tango Therapeutics, Inc.	TNG456	—	RECRUITING	2027-03-31	NCT06810544
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	ZG005 for Injection	—	RECRUITING	2027-04	NCT06903377
Multitude Therapeutics Inc.	AMT-116	—	RECRUITING	2027-05-30	NCT07590531
Revolution Medicines, Inc.	RMC-6236	—	RECRUITING	2027-05-31	NCT05379985
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2027-06	NCT06475300
Tango Therapeutics, Inc.	TNG462	—	RECRUITING	2027-06	NCT06922591
Revolution Medicines, Inc.	RMC-6291	—	RECRUITING	2027-06	NCT06162221
Lumara Bio Oncologics GmbH	[68Ga]Ga-DPI-4452	—	RECRUITING	2027-06	NCT05706129
Dizal Pharmaceuticals	DZD6008	—	RECRUITING	2027-06	NCT07070440
Innate Pharma	IPH5201 + durvalumab + standard chemotherapy	—	RECRUITING	2027-06	NCT05742607
BeBetter Med Inc	BEBT-109 Capsules	—	RECRUITING	2027-06	NCT06514027
Verastem, Inc.	VS-7375	—	RECRUITING	2027-06	NCT07659782
Shanghai Juncell Therapeutics	Autologous Tumor Infiltrating Lymphocytes	—	RECRUITING	2027-06-01	NCT07560111
Shanghai Henlius Biotech	HLX43 dose 1	—	RECRUITING	2027-06-18	NCT07253142
Wayshine Biopharm, Inc.	WSD0922-FU	—	RECRUITING	2027-06-30	NCT06631989
Hummingbird Bioscience	ENV-501	—	RECRUITING	2027-07	NCT06956690
GV20 Therapeutics	GV20-0251	—	RECRUITING	2027-07-16	NCT07070518
Henan Genuine Biotech Co., Ltd.	GEN-725 tablets + Dositinib mesylate tablets	—	RECRUITING	2027-07-31	NCT07362940
Allist Pharmaceuticals, Inc.	JAB 21822	—	RECRUITING	2027-08	NCT05276726
Shanghai JMT-Bio Inc.	JMT203 Injection	—	RECRUITING	2027-08-14	NCT06868849
Johnson & Johnson	Amivantamab	—	RECRUITING	2027-08-17	NCT05498428
Akeso	AK146D1 for injection	—	RECRUITING	2027-08-30	NCT07669779
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Sacituzumab Tirumotecan	—	RECRUITING	2027-08-31	NCT07329322
STCube, Inc.	Nelmastobart and Docetaxel	—	RECRUITING	2027-08-31	NCT07306624
Marengo Therapeutics, Inc.	STAR0602	—	RECRUITING	2027-09	NCT05592626
Iovance Biotherapeutics, Inc.	IOV-4001	—	RECRUITING	2027-09	NCT05361174
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
AstraZeneca	AZD8205	—	RECRUITING	2027-09-29	NCT05123482
Wayshine Biopharm, Inc.	WSD0922-FU Tablets, Dose level A	—	RECRUITING	2027-09-30	NCT06868485
Frontier Medicines Corporation	FMC-376	—	RECRUITING	2027-10	NCT06244771
Pierre Fabre Medicament	STX-241	—	RECRUITING	2027-11-20	NCT06567015
Genmab	Rina-S	—	RECRUITING	2027-11-22	NCT07288177
Teligene US	Sutetinib Maleate Capsule	—	RECRUITING	2027-12	NCT05168566
Teligene US	Sutetinib Maleate Capsule	—	RECRUITING	2027-12	NCT06010329
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-12	NCT07264816
Gilead	TUB-040	—	RECRUITING	2027-12	NCT06303505
VM Oncology, LLC	VMD-928 100 mg Tablet	—	RECRUITING	2027-12	NCT03556228
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1826	—	RECRUITING	2027-12	NCT06754930
Phanes Therapeutics	Mavrostobart (PT199)	—	RECRUITING	2027-12	NCT05431270
Hummingbird Bioscience	HMBD-001	—	RECRUITING	2027-12-01	NCT05910827
Precision Biotech Taiwan Corp.	donor-derived NK cell infusion	—	RECRUITING	2027-12-30	NCT04616209
Abbisko Therapeutics Co, Ltd	ABSK043 in combination with Firmonertinib	—	RECRUITING	2027-12-30	NCT06668103
Suzhou BlueHorse Therapeutics Co., Ltd.	LM103 TILs Injection	—	RECRUITING	2027-12-31	NCT07444437
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
Henan Genuine Biotech Co., Ltd.	Dositinib mesylate tablets	—	RECRUITING	2027-12-31	NCT07231068
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	GTAEXS617	—	RECRUITING	2028-01	NCT05985655
Auricula Biosciences Inc.	WEF-001	—	RECRUITING	2028-01	NCT07148128
Jacobio Pharmaceuticals Co., Ltd.	JAB-8263	—	RECRUITING	2028-01	NCT04686682
AbbVie	Telisotuzumab Vedotin	—	RECRUITING	2028-02	NCT06568939
Johnson & Johnson	Amivantamab	—	RECRUITING	2028-03-02	NCT07586202
Avistone Pharmaceutical（Ningbo）Co., LTD.	PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy	—	RECRUITING	2028-03-08	NCT07063329
Yuhan Corporation	YH42946	—	RECRUITING	2028-03-15	NCT06616766
Hansoh BioMedical R&D Company	HS-20093 for Injection	—	RECRUITING	2028-03-30	NCT07824882
Shanghai Henlius Biotech	HLX43 DOSE 1 (2.0 mg/kg)	—	RECRUITING	2028-04-20	NCT06907615
Betta Pharmaceuticals Co., Ltd.	MCLA-129	—	RECRUITING	2028-04-30	NCT04930432
Genmab	MCLA-158	—	RECRUITING	2028-05	NCT03526835
Dizal Pharmaceuticals	DZD6008	—	RECRUITING	2028-06	NCT07079475
A2 Biotherapeutics Inc.	A2B694	—	RECRUITING	2028-06	NCT06051695
InduPro, Inc.	IDP-001	—	RECRUITING	2028-06	NCT07602842
Akeso	AK138D1	—	RECRUITING	2028-06-18	NCT07623356
GI Innovation, Inc.	GI-101	—	RECRUITING	2028-06-30	NCT04977453
Onchilles Pharma Inc	N17350	—	RECRUITING	2028-07	NCT07339176
Pfizer	PF-08634404	—	RECRUITING	2028-07-29	NCT07489066
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1826	—	RECRUITING	2028-08	NCT07489716
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264+SKB118	—	RECRUITING	2028-08	NCT07697586
Tasca Therapeutics	CP-383	—	RECRUITING	2028-08-15	NCT07030257
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2028-09-15	NCT07680764
Beijing Tide Pharmaceutical Co., Ltd	TCC1727 tablet 90mg	—	RECRUITING	2028-09-30	NCT07371663
BioNTech SE	Pumitamig	—	RECRUITING	2028-10	NCT06841055
Jiangsu HengRui Medicine Co., Ltd.	SHR2554; SHR-A2102	—	RECRUITING	2028-10	NCT07175220

Showing 100 of 585 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Exelixis	XB010	—	RECRUITING	2026-11-23	NCT06545331
ORIC Pharmaceuticals	ORIC-114 Dose 1 + amivantamab	—	RECRUITING	2026-12	NCT06816992
Compass Therapeutics	CTX-8371	—	RECRUITING	2026-12	NCT06150664
Zumutor Biologics Inc.	ZM008	—	RECRUITING	2026-12	NCT06451497
Allist Pharmaceuticals, Inc.	AST2303 Tablets(ABK3376 Tablets) ，25mg	—	RECRUITING	2026-12	NCT06955988
Nuvectis Pharma, Inc.	NXP900	—	RECRUITING	2026-12	NCT07315113
Betta Pharmaceuticals Co., Ltd.	BPI-371153	—	RECRUITING	2026-12	NCT05341557
Revolution Medicines, Inc.	RMC-9805	—	RECRUITING	2026-12-31	NCT06040541
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2026-12-31	NCT06043466
Orano Med Theranostics, SAS	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Kura Oncology, Inc.	Darlifarnib	—	RECRUITING	2027-01	NCT06026410
Shanghai Juncell Therapeutics	Autologous Tumor Infiltrating Lymphocytes	—	RECRUITING	2027-01-01	NCT06473961
Exelixis	Zanzalintinib	—	RECRUITING	2027-01-31	NCT05176483
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM2020 (FGFR2b-ADC)	—	RECRUITING	2027-01-31	NCT07638891
Memgen, Inc.	MEM-288 Intratumoral Injection	—	RECRUITING	2027-02	NCT05076760
Shenzhen TargetRx Co., Ltd.	TGRX-1942	—	RECRUITING	2027-02	NCT06484816
Ankyra Therapeutics, Inc	tolododekin alfa	—	RECRUITING	2027-04	NCT06171750
Valo Therapeutics Oy	PeptiCRAd-1	—	RECRUITING	2027-04-30	NCT05492682
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
Sairopa B.V.	ADU-1805	—	RECRUITING	2027-05	NCT05856981
SHY Therapeutics	SHY-ONC6	—	RECRUITING	2027-05-15	NCT07705334
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
ALX Oncology Inc.	ALX2004	—	RECRUITING	2027-06	NCT07085091
Betta Pharmaceuticals Co., Ltd.	Dose-Escalation (Phase Ia) CFT8919 capsule	—	RECRUITING	2027-06	NCT06641609
Taiho Pharmaceutical Co., Ltd.	AB122	—	RECRUITING	2027-06	NCT04999761
Cytocraft Biopharmaceutical Co., Ltd.	SDT-M001 injection	—	RECRUITING	2027-06-26	NCT07096882
AstraZeneca	T-DXd	—	RECRUITING	2027-06-30	NCT04686305
Ankyra Therapeutics, Inc	tolododekin alfa	—	RECRUITING	2027-06-30	NCT07027514
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Drug: IBI3028	—	RECRUITING	2027-06-30	NCT07589205
AbbVie	Azirkitug	—	RECRUITING	2027-07	NCT05005403
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-11818	—	RECRUITING	2027-08	NCT06917079
Huahui Health	HH160	—	RECRUITING	2027-08	NCT07623369
Nuvectis Pharma, Inc.	NXP900	—	RECRUITING	2027-08	NCT07784959
AstraZeneca	NT-112: Autologous, engineered T Cells targeting KRAS G12D	—	RECRUITING	2027-08-30	NCT06218914
Hangzhou Huasai Biomedicine Co., Ltd.	Cyclophosphamide	DNA	RECRUITING	2027-08-30	NCT07105176
Zymeworks BC Inc.	ZW251	—	RECRUITING	2027-09	NCT07164313
DeuterOncology	DO-2	—	RECRUITING	2027-09	NCT05752552
Dizal Pharmaceuticals	DZD6008	—	RECRUITING	2027-09	NCT06905197
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
Eli Lilly	LY4050784	—	RECRUITING	2027-10	NCT06561685
LG Chem	Phase 1a: LB-LR1109	—	RECRUITING	2027-11	NCT06332755
Aktis Oncology, Inc.	[225Ac]Ac-AKY-1189 (therapeutic)	—	RECRUITING	2027-12	NCT07020117
Iambic Therapeutics, Inc	IAM1363	—	RECRUITING	2027-12	NCT06253871
Aptamer Sciences, Inc.	AST-201	—	RECRUITING	2027-12	NCT06687941
Sutro Biopharma, Inc.	STRO-004	—	RECRUITING	2027-12	NCT07227168
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0610 for Injection	—	RECRUITING	2027-12	NCT07348211
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
LigaChem Biosciences, Inc.	LNCB74	—	RECRUITING	2027-12	NCT06774963
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M24D1	—	RECRUITING	2027-12	NCT07232420
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M09D1	—	RECRUITING	2027-12	NCT07056556
Ascentage Pharma Group Inc.	APG-2449	—	RECRUITING	2027-12	NCT03917043
Bristol-Myers Squibb	MRTX1719	—	RECRUITING	2027-12-10	NCT05245500
Shandong Boan Biotechnology Co., Ltd	BA1302	—	RECRUITING	2027-12-31	NCT06596915
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Seagen, a wholly owned subsidiary of Pfizer	PF-08046054	—	RECRUITING	2028-01-05	NCT05208762
Novartis	68Ga-DFC413	—	RECRUITING	2028-01-16	NCT07630961
NextCure, Inc.	SIM0505 for injection	—	RECRUITING	2028-02	NCT06792552
Sutro Biopharma, Inc.	STRO-006	—	RECRUITING	2028-02	NCT07807345
Avistone Biotechnology Co., Ltd.	PLB1004	—	RECRUITING	2028-02-09	NCT06046495
Boehringer Ingelheim	zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2028-02-29	NCT04886804
Revolution Medicines, Inc.	RMC-5127	—	RECRUITING	2028-04	NCT07349537
Alpha Biopharma (Jiangsu) Co., Ltd.	Zorifertinib and Osimertinib Combination Therapy	—	RECRUITING	2028-04-23	NCT07361705
IDEAYA Biosciences	IDE892	—	RECRUITING	2028-04-30	NCT07277413
Cogent Biosciences, Inc.	CGT4255	—	RECRUITING	2028-05	NCT07361562
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN016	—	RECRUITING	2028-06-30	NCT06868732
Novartis	—	—	RECRUITING	2028-06-30	NCT07801508
Epkin	OKN4395	—	RECRUITING	2028-07	NCT06789172
Pfizer	PF-08046876	—	RECRUITING	2028-07-08	NCT07090499
TwoStep Therapeutics, Inc.	TS-104	—	RECRUITING	2028-08	NCT07814248
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-10	NCT06242470
SystImmune Inc.	SI-B036	—	RECRUITING	2028-10	NCT07857616
PAQ Therapeutics, Inc.	PT0511	—	RECRUITING	2028-10-18	NCT07300150
Nested Therapeutics, Inc	NST-628	—	RECRUITING	2028-11	NCT06326411
Pierre Fabre Medicament	KIN-2787	—	RECRUITING	2028-11-30	NCT04913285
Zelluna Immunotherapy AS	ZI-MA4-1 (TCR-NK cells)	—	RECRUITING	2028-12	NCT07613723
Aktis Oncology, Inc.	[225Ac]Ac-AKY-2519 (therapeutic)	—	RECRUITING	2028-12	NCT07887971
Bristol-Myers Squibb	BMS-986463	—	RECRUITING	2028-12-19	NCT06476808
Immunome, Inc.	IM-1617	—	RECRUITING	2029-01	NCT07578571
Novartis	[68Ga]Ga-DWJ155	—	RECRUITING	2029-01-26	NCT07117214
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
Alterome Therapeutics, Inc.	ALTA3263	—	RECRUITING	2029-05	NCT06835569
Novartis	68Ga-NNS309	—	RECRUITING	2029-05-09	NCT07261631
Eli Lilly	Sofe-M	—	RECRUITING	2029-06	NCT06400472
Kumquat Biosciences Inc.	KQB365	—	RECRUITING	2029-06-30	NCT06720987
EpiBiologics	EPI-326	—	RECRUITING	2029-07	NCT07462377
AstraZeneca	NT-175	—	RECRUITING	2029-07-31	NCT05877599
Seagen, a wholly owned subsidiary of Pfizer	PF-08046050	—	RECRUITING	2029-09-12	NCT06131840
Kumquat Biosciences Inc.	KQB368	—	RECRUITING	2029-12	NCT07542704
AbbVie	ABBV-253	—	RECRUITING	2029-12	NCT07807956
Astellas	gilteritinib	—	RECRUITING	2029-12-31	NCT07140016
BioNTech SE	BNT116	—	RECRUITING	2030-02	NCT05142189
SystImmune Inc.	BL-B01D1	—	RECRUITING	2030-04-20	NCT05983432
Eli Lilly	LY4175408	—	RECRUITING	2030-07	NCT07046923
Chugai Pharmaceutical	AQUA07	—	RECRUITING	2030-08-31	NCT07617337
AbbVie	Lenvatinib	—	RECRUITING	2030-09	NCT06858813
Novartis	[68Ga]Ga-NNS309	—	RECRUITING	2031-01-15	NCT06562192
Pfizer	PF-08098488	—	RECRUITING	2031-01-26	NCT07903415

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Non-Small Cell Lung Cancer

HER2 (22) VEGF (17) EGFR (16) RET (14) PD-1 (11) ROS1 (11)

Novel Non-Small Cell Lung Cancer Drugs by Company (New molecular entities)

20 companies have an FDA-approved novel drug for Non-Small Cell Lung Cancer.

Bristol-Myers Squibb 3 drugs

Novartis 2 drugs

Eli Lilly 2 drugs

Roche 2 drugs

ALECTINIB HYDROCHLORIDE

AstraZeneca 2 drugs

Merck 2 drugs

Pfizer 2 drugs

AVYXA HOLDINGS 1 drug

AXTLE

PEMETREXED DIPOTASSIUM

Takeda 1 drug

Boehringer Ingelheim 1 drug

HERNEXEOS

ZONGERTINIB

NDA 2025

+10 more companies

Reformulations (10 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Non-Small Cell Lung Cancer Drug Targets

Molecular targets of approved and investigational Non-Small Cell Lung Cancer drugs — 59 targets tracked.

EGFR 8 ROS1 7 Dihydrofolate reductase 6 Folylpolyglutamate Synthetase 6 Glycinamide Ribonucleotide Formyltransferase 6 Thymidylate Synthase 6 ALK 6 VEGFA 5 ERBB2 5 Hyaluronan 4 PDCD1 4 CD274 3 NTRK1 3 TRKB 3 TRKC 3 +44 more

Biosimilars (6 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

BIO-THERA SOLUTIONS LTD